FDA grants de novo authorisation to Artera's prostate software
This marks it as an inaugural AI-powered software with the ability to predict long-term results for those with non-metastatic prostate cancer.
This regulatory milestone categorises ArteraAI Prostate as a software as a medical device (SaMD) and enables the use of such AI-assisted tools in qualified pathology laboratories across the US.
The authorisation also sets a new product code for similar future digital pathology risk-stratification applications.
The FDA's decision includes a Predetermined Change Control Plan that allows the company to widen its platform by validating compatibility with more digital pathology scanners with no need for additional 510(k) submissions.
The test was previously granted a breakthrough device designation by the US regulator.
Artera's broader multimodal artificial intelligence (MMAI) platform is already on the market through ArteraAI as a laboratory-developed test (LDT).
The MMAI biomarker test of the company utilises an algorithm that evaluates digital biopsy images and clinical data to forecast the efficacy of hormone therapy and estimate long-term patient outcomes.
This algorithm is the product of extensive development, drawing from vast datasets, including various patients and pathology slides, and has been clinically validated through several Phase III randomised studies.
Artera's portfolio also includes other MMAI-powered products such as the ArteraAI Prostate Biopsy Assay, ArteraAI Prostate, and ArteraAI Breast Test.
Artera co-founder and CEO Andre Esteva said: 'The FDA's decision validates the power of our MMAI platform to deliver on our vision to create AI-guided tools that enable data-backed and tailored treatments for each patient, leading to more confidence throughout the cancer journey, and ultimately, save more lives.'
In February 2025, Artera announced a partnership with Tempus to broaden the availability of the AI-based prostate cancer test.
"FDA grants de novo authorisation to Artera's prostate software" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
20 minutes ago
- The Hill
Mars says M&M's, Starbursts without synthetic dyes coming in 2026
Video above: FDA announces in April 2025 that it will phase out food dyes. (NEXSTAR) — While several other food companies had confirmed they would drop artificial food dyes in response to a mission set forth by Health and Human Services Secretary Robert F. Kennedy Jr. earlier this summer, Mars Wrigley was considered a holdout. That quietly changed late last month. In a late-July statement, which was first reported by Bloomberg on Thursday, Mars Wrigley North America announced it plans to release 'product options' made without artificial dyes in 2026. These options without synthetic dyes will be available only across four of its brands to start, according to the statement: M&M's, Skittles Original, Extra Gum Spearmint, and Starburst Original fruit chews. They'll be available to purchase online throughout the U.S. A spokesperson confirmed to Nexstar that the 'choice products' without artificial dyes will be additions to the current brands. They declined to say whether currently available products will be affected by the dye changes. AT&T reached a $177M settlement over data breaches: Will you get a payment? Mars did not immediately respond to Nexstar's request for additional information, like whether these options will replace others within each brand's portfolio, or if currently available products would be otherwise impacted. 'When we have identified fully effective, scalable solutions across the entire portfolio, we will share additional item commitments and timelines,' the company said in its statement. In April, Food and Drug Administration Commissioner Marty Makary said the agency would move to eliminate several synthetic dyes by the end of next year. That includes Green 3, Red 40, Yellow 5, Yellow 6, Blue 1, and Blue 2. Red 3 was set to be banned in food by 2027 because it caused cancer in laboratory rats; the FDA called for that deadline to move up. The FDA has been relying on companies voluntarily ditching the aforementioned dyes, but does plan to establish a standard and timeline for the food industry to switch to natural alternatives and revoke authorization for dyes not in production. Additionally, the FDA said it would authorize four new natural color additives. Several food manufacturers have already announced plans to ditch synthetic colors. That includes General Mills, Pepsico, ConAgra, Nestle, McCormick, Tyson Foods, Sam's Club, JM Smucker, Hershey, Kraft Heinz, and dozens of companies that make ice cream and frozen dairy desserts. Mars, however, was a holdout as of mid-July. The company now stands to be among the first to have products without artificial dyes available. Artificial dyes are used widely in U.S. foods. In Canada and in Europe — where synthetic colors are required to carry warning labels — manufacturers mostly use natural substitutes. Several states, including California and West Virginia, have passed laws restricting the use of artificial colors in foods. Health advocates have long called for the removal of artificial dyes from foods, citing mixed studies indicating they can cause neurobehavioral problems, including hyperactivity and attention issues, in some children. The FDA has maintained that the approved dyes are safe and that 'the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives.' The FDA currently allows 36 food color additives, including eight synthetic dyes. Removing dyes from the food supply will not address the chief health problems that plague Americans, said Susan Mayne, a Yale University chronic disease expert and former director of the FDA's food center. 'With every one of their announcements, they're focusing in on something that's not going to accomplish what they say it is,' Mayne said of Kennedy's initiatives. 'Most of these food dyes have been in our food supply for 100 years. … So why aren't they driving toward reductions in things that do drive chronic disease rates?'
New York Post
an hour ago
- New York Post
Costco won't sell abortion pills after outcry from religious groups
Costco said it will not offer abortion pills at any of its more than 500 pharmacies nationwide, a move celebrated by religious groups that lobbied against the drug being dispensed by retailers. The Washington state-based wholesaler insisted its decision was based on a lack of customer interest in the medication, Mifepristone, which together with another medicine called misoprostol, is used to end a pregnancy within 10 weeks of gestation. It didn't address whether pressure from conservative organizations influenced the move. 4 A Costco location in the US, one of more than 500 company pharmacies that will not provide Mifepristone. Getty Images A coalition of religious groups including Idaho-based Inspire Investing, the conservative legal organization Alliance Defending Freedom and treasurers and other financial officials from Ohio, Texas, Nevada and Utah had contacted the retailer last year requesting it not carry the drug, according to Bloomberg News. 'It's a very significant win and it's one we hope to build on this coming year,' said Michael Ross, an attorney working with Alliance Defending Freedom's corporate engagement division. Ross indicated the coalition plans to target Walgreens Boots Alliance and CVS next. Both pharmacy chains currently provide mifepristone in states that don't have abortion restrictions. People living in states that have severely limited abortion can obtain the medication by mail from states without such bans. The religious investors sent similar requests last year to Kroger, Walmart and Albertsons alongside Costco, urging them against carrying the medication. Kroger responded that it has never provided abortion pills and continues monitoring regulatory developments. Neither Walmart nor Albertsons currently stocks the medicine. Costco's decision intensifies the ongoing debate about access to the medication. 4 Mifepristone tablets are part of a two-drug regimen to terminate early pregnancies. AP New York City Comptroller Brad Lander had written to various retailers in July last year representing city pension funds, encouraging them to pursue authorization for offering the drug. 'Costco's decision to refuse to dispense mifepristone is disappointing and short-sighted,' a representative from Lander's office told Bloomberg. 'Failure to provide access to proven safe and FDA-approved medication under the guise of 'weak demand' risks isolating customers and undermines the company's credibility.' The Post has sought comment from Costco and Lander. The religious organizations have promised to continue to ramp up pressure. 'We have this momentum,' said Tim Schwarzenberger, who leads corporate engagement at Inspire, which manages the biggest religious exchange-traded fund. 'Now there is a chance to turn to some of the other retailers.' doesn't presently sell the medication, and Schwarzenberger indicated his organization will work to maintain that status. 4 A patient prepares to take mifepristone, which blocks progesterone to end an early-stage pregnancy. AP Amazon didn't provide a response to inquiries. Walgreens declined to comment but referenced information on its website stating: 'The US Supreme Court's ruling on mifepristone access allows Walgreens to continue to dispense mifepristone under the FDA guidelines.' CVS confirmed it distributes mifepristone in certain states where permitted after completing what it called a thorough certification procedure. 'We have a long history of supporting and advancing women's health and we remain focused on meeting their unique health needs. This includes providing access to safe, legal, and evidence-based reproductive health services,' the company stated. The elimination of nationwide abortion protections has resulted in uneven access throughout the US, leading telehealth providers to address some service gaps. Various state legislators have proposed legislation to designate mifepristone as a restricted drug and reduce telehealth availability. According to tracking by the Guttmacher Institute, a nonprofit research organization, lawmakers introduced 32 proposals to prohibit medication abortion and 38 to restrict access during the 2025 legislative period, representing the highest number since the overturn of Roe v. Wade. Data from the Society of Family Planning, an abortion rights organization, shows most abortions in America still occur either at medical facilities or through prescriptions from doctors filled at pharmacies like CVS or Walgreens. A smaller percentage involves prescriptions delivered by mail. 4 Anti-abortion demonstrators rally outside the US Supreme Court in March of last year as debate over medication abortion continues. AP Following increased state-level abortion restrictions, more women have pursued online mifepristone prescriptions for mail delivery. These shipments now represent approximately 25% of American abortions, up from 5 percent before the 2022 Supreme Court decision that ended federal abortion protections. Eight states permitting abortion have enacted protective legislation shielding doctors from prosecution when prescribing mifepristone to patients in states with abortion prohibitions. Ushma Upadhyay, a reproductive sciences professor at the University of California, San Francisco, explained that CVS, Walgreens and similar pharmacies don't provide the medication in states prohibiting abortion, creating difficulties for women seeking the procedure. Telehealth providers can utilize protective laws to ship pills directly to states with restrictions, she noted. This has generated legal disputes. A Texas resident filed a lawsuit in July against a California physician for prescribing abortion medication to his girlfriend. A New York doctor faces criminal charges in Louisiana and a lawsuit from Texas's Attorney General for shipping pills to patients in those states.
Business Wire
2 hours ago
- Business Wire
DeepTempo Expands Leadership Team with Strategic Hires Across Security, Product, and Business Development
SAN FRANCISCO--(BUSINESS WIRE)-- DeepTempo, a pioneer in behavioral threat detection powered by deep learning, today announced three key additions to its leadership team. These hires strengthen DeepTempo's capacity to meet growing enterprise demand for real-time, behavior-first security that outpaces AI-powered threats. As enterprises face a surge of polymorphic, evasive, and AI-enabled threats, DeepTempo is scaling its leadership to match. The company's detection platform, Tempo, is powered by DeepTempo's own LogLM, built in-house from the ground up, alongside related software. Tempo's foundation model, trained on real-world network telemetry, enables defenders to uncover zero-click and agentic threats in real time while minimizing alert fatigue. This foundation in behavior-first detection has made DeepTempo a trusted partner to financial institutions, telecom providers, and critical infrastructure providers. The addition of new executive leadership reflects the company's acceleration in market adoption and its commitment to delivering operational depth, product innovation, and strategic growth. Brennan Lodge Joins DeepTempo as Fractional CISO DeepTempo is proud to announce that Brennan Lodge has transitioned from advisory board member to fractional Chief Information Security Officer (CISO). A recognized cybersecurity leader with prior roles at HSBC, Goldman Sachs, Bloomberg, the Federal Reserve, and J.P. Morgan Chase, Brennan brings deep institutional experience and technical rigor to guide DeepTempo's operational and customer-facing security strategy. His move signals the increasing alignment between DeepTempo's foundational approach to security and the challenges facing large-scale enterprises. 'Brennan's deep understanding of how threat actors exploit modern infrastructure and how security teams can regain the upper hand is already shaping how we scale our impact,' said Evan Powell, CEO of DeepTempo. 'His insights into financial services and regulated sectors will be especially valuable as DeepTempo expands across verticals where threat fidelity, forensic context, and response speed are paramount.' Craig Stancil Appointed Director of Product Management Joining as Director of Product Management is Craig Stancil, whose most recent role at Palo Alto Networks saw him leading the development of advanced threat protection solutions. Craig brings an operator's eye to product innovation, with a track record of delivering real-time capabilities that matter in the heat of an incident. At DeepTempo, Craig will lead the evolution of Tempo and its LogLM foundation model, continuing the fight against the world's most advanced threats and ensuring the platform meets the dynamic needs of defenders across cloud-native, hybrid, and highly regulated environments. Fred Smith Named VP of Business and Corporate Development Also joining the team is Fred Smith as Vice President of Business and Corporate Development. Fred will lead strategic partnerships, ecosystem growth, and M&A strategy. His cross-functional expertise will play a pivotal role in expanding DeepTempo's integration footprint across MSSPs, hyperscalers, and critical infrastructure sectors. With experience at the intersection of business growth and go-to-market innovation, Fred will be instrumental in accelerating DeepTempo's reach and long-term platform value. These leadership hires follow a period of rapid momentum for DeepTempo, including recognition as a finalist in the Snowflake Startup Challenge and a series of successful deployments across financial, telecommunications, and government sectors. Tempo, powered by DeepTempo's proprietary LogLM foundation model trained on real-world network telemetry, detects zero-click, agentic, and polymorphic threats in real time. About DeepTempo DeepTempo offers deep-learning-based cybersecurity solutions that safeguard enterprises and service providers against cyberattacks. Leveraging its foundation LogLMs, the company's cybersecurity solutions are on the Snowflake Native App Marketplace and also available for deployment in on-premise security data lakes, helping organizations optimize security spending and enhance operational efficiency while maintaining robust threat protection without lock-ins. To find out more, go to or check out the company's LinkedIn page, YouTube channel, and Medium posts.
